VR Logo

Capricor Therapeutics Inc. (CAPR) download report


Healthcare | Biotechnology & Pharma Research

Capricor Therapeutics Inc. (CAPR) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

IPO Date: 13-Feb-2007

Exec. Chairman: Dr. Frank Isaac Litvack FACC, M.D.

Co-Founder, Pres, CEO & Director: Dr. Linda Marbán Ph.D.

Listing: NASDAQ: CAPR

Country: United States

Headquarters: San Diego, CA

Website: https://www.capricor.com

Key Facts

Market cap: $89.51 Mln

Revenue (TTM): $-0.04 Mln

Earnings (TTM): $-22.69 Mln

Cash: $58.33 Mln

Total Debt: $2.80 Mln

Insider's Holding: 2.80%

Liquidity: Low

52 Week range: $2.56 - 5.85

Shares outstanding: 24,324,200

10 Years Aggregate:

  • CFO: $-95.77 Mln
  • EBITDA: $-77.70 Mln
  • Net Profit: $-82.74 Mln

Stock Performance

Time Period Capricor Therapeutics (CAPR) S&P BSE Sensex* S&P Small-Cap 600*
YTD25.60-8.62-18.78
1 month1.10-4.54-8.00
3 months7.29-10.19-13.65
1 Year-28.271.43-17.19
3 Years3.4910.146.10
5 Years-15.0111.265.87
10 Years-22.9711.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Capricor Therapeutics (CAPR) S&P Small-Cap 600 S&P BSE Sensex
2021-14.5825.2721.99
2020167.979.5715.75
2019-68.7820.8614.38
2018-73.86-9.705.87
2017-40.6011.7327.91
2016-13.4624.741.95
2015-18.04-3.36-5.03